Momenta Pharmaceuticals, Inc. (MNTA) Shares Bought by Tocqueville Asset Management L.P.

Tocqueville Asset Management L.P. increased its holdings in shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 3.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 280,488 shares of the biotechnology company’s stock after buying an additional 8,150 shares during the quarter. Tocqueville Asset Management L.P. owned 0.38% of Momenta Pharmaceuticals worth $5,189,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of MNTA. BlackRock Inc. grew its holdings in shares of Momenta Pharmaceuticals by 64,825.8% during the first quarter. BlackRock Inc. now owns 8,774,070 shares of the biotechnology company’s stock valued at $117,134,000 after buying an additional 8,760,556 shares in the last quarter. State Street Corp grew its holdings in shares of Momenta Pharmaceuticals by 30.8% during the first quarter. State Street Corp now owns 2,455,449 shares of the biotechnology company’s stock valued at $32,776,000 after buying an additional 577,504 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Momenta Pharmaceuticals by 322.9% during the second quarter. Acadian Asset Management LLC now owns 696,138 shares of the biotechnology company’s stock valued at $11,762,000 after buying an additional 531,525 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Momenta Pharmaceuticals by 186.4% during the second quarter. Renaissance Technologies LLC now owns 797,400 shares of the biotechnology company’s stock valued at $13,476,000 after buying an additional 519,000 shares in the last quarter. Finally, FMR LLC grew its holdings in shares of Momenta Pharmaceuticals by 3.3% during the second quarter. FMR LLC now owns 11,125,193 shares of the biotechnology company’s stock valued at $188,015,000 after buying an additional 351,743 shares in the last quarter. Institutional investors and hedge funds own 93.89% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.com-unik.info/2017/11/05/momenta-pharmaceuticals-inc-mnta-shares-bought-by-tocqueville-asset-management-l-p.html.

Momenta Pharmaceuticals, Inc. (MNTA) opened at $13.20 on Friday. Momenta Pharmaceuticals, Inc. has a 52 week low of $10.75 and a 52 week high of $19.90.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.03. The firm had revenue of $24.09 million for the quarter, compared to the consensus estimate of $29.58 million. Momenta Pharmaceuticals had a negative return on equity of 16.20% and a negative net margin of 55.61%. The business’s quarterly revenue was down 17.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.26) earnings per share. analysts expect that Momenta Pharmaceuticals, Inc. will post -0.99 EPS for the current fiscal year.

A number of research analysts have recently weighed in on the company. Cowen and Company set a $15.00 price target on Momenta Pharmaceuticals and gave the company a “hold” rating in a report on Wednesday. Zacks Investment Research downgraded Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Robert W. Baird downgraded Momenta Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their price target for the company from $22.00 to $15.00 in a report on Friday, October 6th. ValuEngine downgraded Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Finally, J P Morgan Chase & Co restated a “hold” rating and issued a $14.00 target price on shares of Momenta Pharmaceuticals in a research note on Thursday, October 5th. Three analysts have rated the stock with a sell rating and nine have assigned a hold rating to the company. Momenta Pharmaceuticals has an average rating of “Hold” and a consensus price target of $15.00.

In other news, President Craig A. Wheeler sold 35,667 shares of the company’s stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $19.03, for a total transaction of $678,743.01. Following the completion of the sale, the president now owns 286,121 shares in the company, valued at approximately $5,444,882.63. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, President Craig A. Wheeler sold 16,953 shares of the company’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $16.94, for a total value of $287,183.82. The disclosure for this sale can be found here. In the last quarter, insiders have sold 79,463 shares of company stock valued at $1,411,098. 4.40% of the stock is currently owned by corporate insiders.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

What are top analysts saying about Momenta Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Momenta Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit